DOI: 10.36347/sajb.2015.v03i11.012

Pages: 949-956

ST elevated myocardial infarction (STEMI), non-ST elevated myocardial infarction (NSTEMI) and unstable anginas (UA) are continual spectrum of coronary artery disease (CAD). These are terminal events arising as a result of coronary artery atherosclerosis and superimposed thrombosis. In patients with acute coronary syndrome (ACS) and myocardial infarction (MI), it is desirable to identify a sensitive serum marker that is closely related to the degree of myocardial damage, provides prognostic information and can be measured rapidly. In our study, a total of 91 patients of either sex aged 20 to 60 years are recruited for this study, of which 30 are STEMI, 31 are NSTEMI / unstable angina and 30 are age and sex matched healthy controls. Of the total 91 subjects 30 were of STEMI (Group 1), 15 were of NSTEMI (Group 2), 16 were of unstable angina (Group 3) and 30 were controls (Group 4). In this study , out of total 30 cases of STEMI 11 had inferior wall Myocardial Infarction (MI), 5 had Antero septal wall MI, 11 had Anterior wall MI, 2 had Anterolateral wall MI and 1 had Apical wall MI. Of the total 59 patients of CAD (STEMI, NSTEMI, and UA) in which MPO determination was done, 17 had complications. In these patients MPO level was higher as compared to 42 patients in whom complications were absent. In patients in whom complications were present MPO level was 17.86±5.75 EU/ml, which was significantly higher, as compared to patients in whom complications were absent. This correlation was statistically significant. In complicated ACS, irrespective of other risk factors, MPO is significantly raised as compared to controls & can be used to predict immediate clinical complication. MPO is an early marker of plaque, destabilization in the overall spectrum of atherogenesis, it was postulated that it will be extremely useful in risk stratification of patients with chest pain, thereby preventing complications with help of timely intervention.